FOSUN 复星 復 星 國 際 有 限 公 司 FOSUN INTERNATIONAL LIMITED (在香港註冊成立之有限公司) (股份代號 : 00656) 2020 ion& Win 歸屬於母公司股東 之利潤為 人民幣 百萬元 8,017.9 創‧贏 2020年，可能是復星最具挑戰的一年，但也是最好的一年。疫情發生後，我們在全球抗疫中所形成的戰時 機制和戰鬥精神，驅動全年業務迸發出十足的韌勁。疫情的洗禮也使我們長期積累的「產業運營+產業投 資」、FC2M、全球化、科技創新等核心能力得到了全面升級，進化出了一個更強大的復星。 今年復星年報的主題是「創‧贏」。「創」是指復星一直重視創新，我們認識到只有加大創新研發投入，才 可打造全球一流產品。也正是我們長期以來對產業科創的堅定投入和積累，以及憑藉復星多元化及全球化的 業務組合、「產業運營+產業投資」的發展模式、從抗疫期間所延續下來的戰時狀態，才使得我們有效抵禦 了外部環境的衝擊，推動集團業績展現出十足的韌勁，與各利益相關方實現共「贏」和多「贏」的局面。 2021年是復星「蛻變」的新起點。面對產業互聯網時代所蘊含的巨大機遇，我們在原先聚焦打造好產品的基 礎 ...

[Financial Highlights](index=2&type=section&id=%E8%B2%A1%E5%8B%99%E6%91%98%E8%A6%81) This section presents a concise overview of the company's key financial performance indicators for 2019, including revenue, profit, and per-share metrics 2019 Financial Highlights (RMB Million) | Indicator | 2019 | 2018 (Restated) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | **Total Revenue** | **142,982.1** | **109,351.6** | **30.7%** | | Health | 33,133.0 | 29,093.3 | 13.9% | | Happiness | 67,557.5 | 44,936.4 | 50.3% | | Wealth | 43,370.0 | 36,097.4 | 20.1% | | **Profit Attributable to Parent Company Shareholders** | **14,800.9** | **13,406.4** | **10.4%** | | Health | 1,561.4 | 1,484.7 | 5.2% | | Happiness | 2,826.7 | 2,276.5 | 24.2% | | Wealth | 10,412.8 | 9,645.2 | 8.0% | | **Earnings Per Share (Basic, RMB)** | **1.73** | **1.57** | **10.2%** | | **Dividend Per Share (HKD)** | **0.40** | **0.37** | **8.1%** | [Letter to Shareholders](index=3&type=section&id=%E8%87%B4%E8%82%A1%E6%9D%B1%E7%9A%84%E4%BF%A1) The letter from the board outlines the company's strategic focus, operational achievements, and future outlook, emphasizing resilience and growth initiatives 2019 Performance Highlights | Indicator | Amount | Year-on-Year Growth | | :--- | :--- | :--- | | Operating Revenue | RMB 143 Billion | 31% | | Profit Attributable to Parent Company Shareholders | RMB 14.8 Billion | 10% | - Facing the COVID-19 pandemic, Fosun leveraged its global resources to allocate supplies and collaborated with BioNTech to develop an mRNA vaccine, demonstrating the strong power of its global organization and ecosystem[9](index=9&type=chunk)[10](index=10&type=chunk) - In the post-pandemic era, the company will focus on upgrading China's family consumption industry, strengthening product "familialization," "healthification," and "online presence" - Key to 2020 growth is "focus," optimizing asset allocation, concentrating on core industries, and striving to make each core industry a leader, through refined management, increased innovation and R&D, enhanced vertical industry integration, and emphasis on ecosystem synergy[10](index=10&type=chunk) - The company underwent a high-level organizational reshuffle, with Wang Qunbin promoted to Co-Chairman and Chen Qiyu and Xu Xiaoliang appointed Co-CEOs, aiming to strengthen top-level design and enhance organizational vitality and operational efficiency[11](index=11&type=chunk) - The company continued to reduce its debt-to-asset ratio, with total debt as a percentage of total capital at **53.5%** as of the end of the reporting period[11](index=11&type=chunk) [Fosun's Anti-Epidemic Efforts](index=7&type=section&id=%E5%BE%A9%E6%98%9F%E6%8A%97%E7%96%AB%E6%95%85%E4%BA%8B) This section details Fosun's global response to the COVID-19 pandemic, including medical supply procurement, vaccine development, and healthcare support - Following the outbreak, Fosun swiftly initiated a global medical supply allocation plan, establishing a procurement network covering 23 countries to urgently acquire protective materials for frontline support[13](index=13&type=chunk) - Leveraging its industry accumulation in the big health sector, Fosun Pharma partnered with Germany's BioNTech for exclusive development and commercialization of mRNA-based COVID-19 vaccine products in China[13](index=13&type=chunk) - Fosun's 27 hospitals became designated COVID-19 treatment facilities, dispatching over 240 medical personnel to support the Hubei frontline, with Wuhan Jihe Hospital treating 515 patients in 51 days, achieving zero mortality and zero infection among medical staff[14](index=14&type=chunk) - Since March 1, Fosun launched the second phase of its anti-epidemic efforts, dispatching over **2.52 million** pieces of medical protective supplies to key overseas countries including Italy, the United States, and Germany[16](index=16&type=chunk) [Business Overview](index=9&type=section&id=%E6%A5%AD%E5%8B%99%E6%A6%82%E8%A6%BD) This section provides a comprehensive overview of the group's core business segments, highlighting key financial and operational achievements and future strategic directions [Financial Highlights Review](index=10&type=section&id=%E8%B2%A1%E5%8B%99%E4%BA%AE%E9%BB%9E%E5%9B%9E%E9%A1%A7) In 2019, the group achieved record-high performance with total revenue growing 31% to RMB 142.98 billion and net profit attributable to parent company shareholders increasing 10% to RMB 14.80 billion, maintaining a stable debt-to-capital ratio 2019 Key Financial Indicators | Indicator | 2019 | Year-on-Year Growth | | :--- | :--- | :--- | | Total Revenue | RMB 142.98 Billion | 31% | | Profit Attributable to Parent Company Shareholders | RMB 14.80 Billion | 10% | | Industrial Operating Profit | RMB 11.13 Billion | 21% | | Total Debt to Total Capital Ratio | 53.5% | -0.2 p.p. | | Return on Equity (ROE) | 12.8% | Stable | | Total Annual Dividend | HKD 0.40 per share | 8.1% | [Business Highlights Review](index=10&type=section&id=%E6%A5%AD%E5%8B%99%E4%BA%AE%E9%BB%9E%E5%9B%9E%E9%A1%A7) The group deepened its focus on Health, Happiness, and Wealth segments, achieving significant revenue growth in Happiness and steady performance in Health and Wealth, driven by strategic initiatives and strong market presence [Health Segment](index=10&type=section&id=%E5%81%A5%E5%BA%B7%E6%A5%AD%E5%8B%99) The Health segment achieved a 14% revenue increase, with significant R&D investments and progress in innovative drug development Health Segment Financial Performance (RMB) | Indicator | 2019 | 2018 | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Total Revenue | 33.13 Billion | 29.09 Billion | 14% | | Profit Attributable to Parent Company Shareholders | 1.56 Billion | 1.48 Billion | 5% | - Fosun Pharma's R&D investment in 2019 reached **RMB 3.46 billion**, accounting for **12%** of revenue, achieving significant progress in T-cell therapy, biosimilars, and innovative target projects[20](index=20&type=chunk) [Happiness Segment](index=11&type=section&id=%E5%BF%AB%E6%A8%82%E6%A5%AD%E5%8B%99) The Happiness segment saw a substantial 50% revenue growth and 24% profit increase, primarily driven by strong performance from Yuyuan Inc. and Fosun Tourism Group Happiness Segment Financial Performance (RMB) | Indicator | 2019 | 2018 | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Total Revenue | 67.56 Billion | 44.94 Billion | 50% | | Profit Attributable to Parent Company Shareholders | 2.83 Billion | 2.28 Billion | 24% | - Yuyuan Inc.'s jewelry and fashion business revenue reached **RMB 20.46 billion**, a **23%** year-on-year increase, with net store additions of **669** to a total of **2,759** stores[22](index=22&type=chunk) - Fosun Tourism Group's Sanya Atlantis project performed exceptionally well, with 2019 operating revenue reaching **RMB 1.31 billion**, a year-on-year increase of over **74.2%**, and attracting **5.2 million** visitors for the year[22](index=22&type=chunk) [Wealth Segment](index=12&type=section&id=%E5%AF%8C%E8%B6%B3%E6%A5%AD%E5%8B%99) The Wealth segment recorded a 20% revenue growth, with notable profit increases in the insurance and financial sectors Wealth Segment Financial Performance (RMB) | Indicator | 2019 | 2018 | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Total Revenue | 43.37 Billion | 36.10 Billion | 20% | | Profit Attributable to Parent Company Shareholders | 10.41 Billion | 9.65 Billion | 8% | - Profit attributable to parent company shareholders for the insurance segment was **RMB 2.61 billion**, a **9%** year-on-year increase; for the financial segment, it was **RMB 1.50 billion**, a **21%** year-on-year increase; and for the investment segment, it was **RMB 6.31 billion**, a **5%** year-on-year increase[23](index=23&type=chunk)[25](index=25&type=chunk) [2020 Strategic Focus](index=13&type=section&id=2020%E5%B9%B4%E5%BE%A9%E6%98%9F%E5%A2%9E%E9%95%B7%E7%9A%84%E9%97%9C%E9%8D%B5%E5%AD%97%EF%BC%8D%E3%80%8C%E8%81%9A%E7%84%A6%E3%80%8D) Following global expansion, Fosun's 2020 strategy emphasizes 'focus' to enhance competitiveness and ROE, concentrating on family clients, C2M, innovation, and ecosystem synergy - The company will strategically focus on three types of assets: "basic assets" that contribute stable profits and cash flow to the group; "high-growth assets" with an ROE target of **≥15%** and high profit growth; and "innovation-leading assets" that are strategically positioned in innovative sectors and offer high synergy[26](index=26&type=chunk) [Management Discussion and Analysis](index=14&type=section&id=%E7%AE%A1%E7%90%86%E5%B1%A4%E8%A8%8E%E8%AB%96%E8%88%87%E5%88%86%E6%9E%90) This section provides an in-depth review of the group's financial performance, asset allocation, and operational highlights across its key business segments for the reporting period [Business Review and Asset Allocation](index=14&type=section&id=%E6%A5%AD%E5%8B%99%E5%9B%9E%E9%A1%A7%E8%88%87%E8%B3%87%E7%94%A2%E9%85%8D%E7%BD%AE) As of year-end 2019, the group's total assets reached RMB 715.68 billion, with Wealth, Happiness, and Health segments accounting for the largest proportions, contributing to a 10.4% increase in net profit attributable to parent company shareholders Group Asset Allocation (As of December 31, 2019) | Segment | Total Assets (RMB Million) | Proportion | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Health | 91,740.1 | 12.8% | 5.6% | | Happiness | 178,393.9 | 24.9% | 22.3% | | Wealth | 461,507.4 | 64.5% | 9.3% | | **Total** | **715,681.2** | **100%** | **12.0%** | [Health Segment](index=17&type=section&id=%E5%81%A5%E5%BA%B7%E6%A5%AD%E5%8B%99) In 2019, the Health segment's revenue grew 13.9% to RMB 33.13 billion, with net profit attributable to parent company shareholders increasing 5.2%, driven by steady growth from Fosun Pharma and significant R&D advancements [Fosun Pharma](index=19&type=section&id=%E5%BE%A9%E6%98%9F%E9%86%AB%E8%97%A5) Fosun Pharma achieved robust revenue and profit growth in 2019, supported by stable pharmaceutical operations and strategic divestitures Fosun Pharma 2019 Performance | Indicator | Amount (RMB Million) | Year-on-Year Growth | | :--- | :--- | :--- | | Operating Revenue | 28,389 | 14.87% | | Net Profit | 3,744 | 23.96% | | Net Profit Attributable to Shareholders | 3,322 | 22.66% | | R&D Investment | 3,463 | 38.15% | - Profit growth primarily stemmed from stable growth in the pharmaceutical segment, high-speed revenue growth from multiple products, and profit contribution from the sale of United Family Healthcare equity[42](index=42&type=chunk) [Henlius](index=20&type=section&id=%E5%BE%A9%E5%AE%8F%E6%BC%A2%E9%9C%96) Henlius listed on the HKEX in September 2019, generating revenue from core product commercialization but incurring increased losses due to R&D and operational investments - Henlius listed on the Hong Kong Stock Exchange in September 2019, with total revenue of **RMB 90.9 million**, mainly from core product commercialization; however, due to R&D and operational investments, losses expanded from **RMB 505 million** in 2018 to **RMB 876 million**[44](index=44&type=chunk) [Gland Pharma](index=21&type=section&id=Gland%20Pharma) Gland Pharma reported significant revenue and net profit growth in 2019, driven by its international R&D strategy and numerous FDA approvals for generic drugs - Gland Pharma's 2019 revenue translated to **RMB 2.51 billion**, a **31.0%** year-on-year increase; net profit after considering valuation amortization was **RMB 513 million**, an **81.1%** year-on-year increase; the company pursued an international R&D strategy, with **15** generic drug products approved for market by the US FDA during the year[45](index=45&type=chunk) [Happiness Segment](index=22&type=section&id=%E5%BF%AB%E6%A8%82%E6%A5%AD%E5%8B%99) In 2019, the Happiness segment's revenue surged 50.3% to RMB 67.56 billion, with net profit attributable to parent company shareholders rising 24.2%, primarily due to the consolidation of Yuyuan Inc. and growth from Fosun Tourism Group [Yuyuan Inc.](index=24&type=section&id=%E8%B1%AB%E5%9C%92%E8%82%A1%E4%BB%BD) Yuyuan Inc. demonstrated strong performance in 2019, particularly in its jewelry and fashion business, expanding its store network and pursuing strategic acquisitions Yuyuan Inc. 2019 Performance | Indicator | Amount (RMB Million) | Year-on-Year Growth | | :--- | :--- | :--- | | Operating Revenue | 42,912 | 26.47% | | Net Profit Attributable to Shareholders | 3,208 | 5.79% | - The jewelry and fashion business performed outstandingly, with revenue increasing **22.66%** year-on-year to **RMB 20.46 billion**, and net store additions of **669** to a total of **2,759** stores; concurrently, the company accelerated external investment and M&A through acquisitions of IGI and Seagull Watch[50](index=50&type=chunk)[52](index=52&type=chunk) [Fosun Tourism Group](index=25&type=section&id=%E5%BE%A9%E6%98%9F%E6%97%85%E6%96%87) Fosun Tourism Group achieved substantial profit growth in 2019, with the Sanya Atlantis project showing outstanding operational performance and visitor numbers Fosun Tourism Group 2019 Performance | Indicator | Amount (RMB Million) | Year-on-Year Growth | | :--- | :--- | :--- | | Total Revenue | 17,337.2 | 6.6% | | Profit Attributable to Parent Company Shareholders | 608.7 | 97.4% | | Adjusted EBITDA | 3,729.4 | 79.9% | - The Sanya Atlantis project performed remarkably, with 2019 operating revenue reaching **RMB 1.31 billion**, a year-on-year increase of over **74.2%**, and attracting **5.2 million** visitors[55](index=55&type=chunk) [Wealth Segment](index=29&type=section&id=%E5%AF%8C%E8%B6%B3%E6%A5%AD%E5%8B%99) The Wealth segment, comprising insurance, finance, and investment, saw varied performance in 2019, with insurance and finance sectors achieving profit growth while investment income slightly decreased [Insurance](index=29&type=section&id=%E4%BF%9D%E9%9A%AA) The Insurance segment reported a 32.1% revenue increase and 9.4% profit growth in 2019, driven by strong market positioning and international expansion Insurance Segment 2019 Performance | Indicator | Amount (RMB Million) | Year-on-Year Growth | | :--- | :--- | :--- | | Revenue | 31,261.9 | 32.1% | | Profit Attributable to Parent Company Shareholders | 2,606.8 | 9.4% | - Fosun Portugal Insurance continued to consolidate its market leadership, holding a total market share of **25.5%**, and accelerated international expansion through the acquisition of La Positiva in Peru[62](index=62&type=chunk) - Peak Reinsurance's premium income reached **USD 1.66 billion**, showing stable year-on-year growth, with net profit reaching **USD 37.7 million**[65](index=65&type=chunk) - Fosun-Prudential Life Insurance's premium income increased **222.6%** year-on-year to **RMB 4.06 billion**, but net loss expanded to **RMB 214 million**[67](index=67&type=chunk) [Finance](index=32&type=section&id=%E9%87%91%E8%9E%8D) The Finance segment maintained stable revenue in 2019 while achieving a 20.5% increase in net profit attributable to parent company shareholders, supported by asset management growth and improved asset quality Finance Segment 2019 Performance | Indicator | Amount (RMB Million) | Year-on-Year Change | | :--- | :--- | :--- | | Revenue | 2,492.6 | 0.4% | | Profit Attributable to Parent Company Shareholders | 1,501.0 | 20.5% | - German private bank H&A's assets under management reached **Euro 142 billion**, a **14.5%** year-on-year increase[70](index=70&type=chunk) - Banco Comercial Português (BCP)'s net profit attributable to bank shareholders was **Euro 302 million**, remaining stable, with significant improvement in asset quality[73](index=73&type=chunk) [Investment](index=34&type=section&id=%E6%8A%95%E8%B3%87) The Investment segment experienced a slight revenue decrease but achieved a 4.8% profit growth in 2019, with strategic acquisitions and diversified portfolio contributions Investment Segment 2019 Performance | Indicator | Amount (RMB Million) | Year-on-Year Change | | :--- | :--- | :--- | | Revenue | 9,615.5 | -3.3% | | Profit Attributable to Parent Company Shareholders | 6,305.0 | 4.8% | - Fosun Capital's assets under management approached **RMB 16 billion**, leading the acquisition of FFT, a benchmark enterprise in Germany's "Industry 4.0," during the year[76](index=76&type=chunk) - Nanjing Iron & Steel Co., Ltd.'s operating revenue increased **9.91%** year-on-year to **RMB 47.97 billion**, but net profit attributable to parent company shareholders decreased **34.98%** year-on-year to **RMB 2.61 billion**[79](index=79&type=chunk) - Hainan Mining expanded into the oil and gas sector by acquiring a **51%** stake in Roc Oil, achieving a **47.84%** revenue increase and turning losses into profits during the reporting period[80](index=80&type=chunk) [Financial Review](index=41&type=section&id=%E8%B2%A1%E5%8B%99%E5%9B%9E%E9%A1%A7) This section reviews the group's financial position, including interest expenses, taxation, earnings per share, capital expenditure, debt structure, liquidity, and risk management policies, highlighting stable debt ratios and sufficient financing sources - Net interest expense in 2019 was **RMB 9.89 billion**, a significant increase from **RMB 6.89 billion** in 2018, primarily due to an increase in total borrowings and interest rates[93](index=93&type=chunk) - Basic earnings per share were **RMB 1.73**, a **10.2%** year-on-year increase; equity per share attributable to parent company shareholders was **RMB 14.35**, an increase of **RMB 1.65** from the previous year[94](index=94&type=chunk)[95](index=95&type=chunk) Debt and Liquidity Overview (RMB Million) | Indicator | December 31, 2019 | December 31, 2018 | | :--- | :--- | :--- | | Total Debt | 208,287.1 | 186,140.4 | | Cash and Bank Balances and Time Deposits | 94,900.5 | 106,316.5 | | Total Debt to Total Capital Ratio | 53.5% | 53.7% | - Net cash flow from operating activities was **RMB 7.83 billion**, net cash flow used in investing activities was **RMB 12.44 billion**, and net cash flow used in financing activities was **RMB 4.75 billion**[107](index=107&type=chunk)[108](index=108&type=chunk) [Five-Year Statistics](index=46&type=section&id=%E4%BA%94%E5%B9%B4%E7%B5%B1%E8%A8%88) This section provides a five-year summary of key financial data from 2015 to 2019, illustrating the group's long-term performance trends in equity, debt, profit, and earnings per share Five-Year Financial Data Summary (2015-2019) | Indicator (RMB Million) | 2015 | 2016 | 2017 | 2018 | 2019 | | :--- | :--- | :--- | :--- | :--- | :--- | | Equity Attributable to Parent Company Shareholders | 75,744.3 | 92,367.0 | 100,960.8 | 108,528.8 | 122,552.3 | | Total Debt | 115,110.0 | 126,276.8 | 150,456.5 | 186,140.4 | 208,287.1 | | Profit Attributable to Parent Company Shareholders | 8,038.3 | 10,268.2 | 13,161.3 | 13,406.4 | 14,800.9 | | Basic Earnings Per Share (RMB) | 1.06 | 1.19 | 1.53 | 1.57 | 1.73 | | EBITDA | 24,422.5 | 23,891.3 | 30,789.2 | 32,710.4 | 44,103.3 | [Corporate Governance Report](index=47&type=section&id=%E4%BC%81%E6%A5%AD%E7%AE%A1%E6%B2%BB%E5%A0%B1%E5%91%8A) This report details the company's adherence to corporate governance principles and code provisions, emphasizing board structure, committee functions, and risk management systems to ensure high standards of governance - During the reporting period, the company applied the principles of the Corporate Governance Code and fully complied with all code provisions, committed to achieving a high level of corporate governance[118](index=118&type=chunk) - The Board of Directors comprises executive directors, non-executive directors, and independent non-executive directors, with independent non-executive directors constituting one-third of the board members, meeting listing rule requirements, and the board considers all independent non-executive directors to be independent[121](index=121&type=chunk)[123](index=123&type=chunk) - The Board has established an Audit Committee, Remuneration Committee, Nomination Committee, and Environmental, Social and Governance (ESG) Committee, with the majority of members in each committee being independent non-executive directors to ensure independence and professional oversight[133](index=133&type=chunk)[134](index=134&type=chunk)[135](index=135&type=chunk) - The Board is responsible for evaluating and maintaining effective risk management and internal control systems, and during the reporting period, the Board reviewed the systems and deemed them effective and adequate[142](index=142&type=chunk)[143](index=143&type=chunk) [Biographies of Directors and Senior Management](index=58&type=section&id=%E8%91%A3%E4%BA%8B%E5%8F%8A%E9%AB%98%E7%B4%9A%E7%AE%A1%E7%90%86%E4%BA%BA%E5%93%A1%E7%B0%A1%E5%8E%B6) This section provides detailed biographies of the company's executive directors, non-executive directors, independent non-executive directors, and senior management, outlining their professional backgrounds and roles - This section provides detailed information on the personal resumes, professional backgrounds, and positions held within and outside the group by the company's executive directors, non-executive directors, independent non-executive directors, and senior management[149](index=149&type=chunk)[150](index=150&type=chunk)[151](index=151&type=chunk) [Directors' Report](index=62&type=section&id=%E8%91%A3%E4%BA%8B%E6%9C%83%E5%A0%B1%E5%91%8A) This report provides an overview of the group's principal activities, financial performance, and key operational highlights for the year, along with proposed dividend distributions and share repurchase details [Principal Activities and Performance](index=62&type=section&id=%E4%B8%BB%E8%A6%81%E6%A5%AD%E5%8B%99%E8%88%87%E6%A5%AD%E7%B8%BE) As an innovation-driven family consumption industry group, the company focuses on Health, Happiness, and Wealth segments, with detailed performance and financial status available in the financial statements, and a proposed final dividend of HKD 0.27 per share - The company's principal activities include three major segments: Health (pharmaceuticals, healthcare services), Happiness (tourism, fashion), and Wealth (insurance, finance, investment)[164](index=164&type=chunk) - The Board of Directors recommends a final dividend of **HKD 0.27** per share for the year ended December 31, 2019[166](index=166&type=chunk) [Share Repurchases](index=63&type=section&id=%E8%B3%BC%E5%9B%9E%E3%80%81%E8%B4%96%E5%9B%9E%E6%88%96%E5%87%BA%E5%94%AE%E6%9C%AC%E5%85%AC%E5%8F%B8%E7%9A%84%E4%B8%8A%E5%B8%82%E8%AD%89%E5%88%B8) During the reporting period, the company repurchased a total of 15,650,000 shares on the Hong Kong Stock Exchange for approximately HKD 159 million, all of which have been cancelled 2019 Share Repurchase Details | Repurchase Month | Total Shares Repurchased | Total Consideration Paid (HKD) | | :--- | :--- | :--- | | May 2019 | 6,800,000 | 71,410,329.60 | | June 2019 | 3,950,000 | 39,349,510.00 | | September 2019 | 3,200,000 | 31,581,784.73 | | October 2019 | 1,700,000 | 16,255,649.90 | | **Total** | **15,650,000** | **158,597,274.23** | [Human Resources and Incentive Schemes](index=64&type=section&id=%E4%BA%BA%E5%8A%9B%E8%B3%87%E6%BA%90%E8%88%87%E6%BF%80%E5%8B%B5%E8%A8%88%E5%8A%83) As of year-end 2019, the group employed approximately 71,000 people, focusing on talent development and employee care through multi-tiered share award and share option schemes to align employee interests with long-term group development - During the reporting period, the company granted a total of **6,703,000** award shares to **102** selected participants under the share award scheme[180](index=180&type=chunk)[181](index=181&type=chunk) - During the reporting period, the company granted a total of **86,260,000** share options under the new share option scheme[185](index=185&type=chunk)[187](index=187&type=chunk) - Major subsidiaries of the group, such as Fosun Tourism Group, Yuyuan Inc., and Gland Pharma, have also adopted their respective share option incentive schemes[191](index=191&type=chunk)[202](index=202&type=chunk)[206](index=206&type=chunk) [Principal Risks and Responses](index=86&type=section&id=%E4%B8%BB%E8%A6%81%E9%A2%A8%E9%9A%AA%E5%8F%8A%E6%87%89%E5%B0%8D) The group identifies, assesses, and monitors various operational risks through a comprehensive risk management system, including strategic, market, credit, liquidity, insurance, compliance, operational, reputational, and capital management risks, with corresponding control strategies in place - The group faces principal risks including: - **Strategic Risk**: Uncertainty in trend judgment due to broad investment areas and global distribution - **Market Risk**: Risk of loss due to unfavorable changes in interest rates, stock prices, exchange rates - **Credit Risk**: Risk of counterparty default - **Liquidity Risk**: Risk of inability to obtain sufficient funds in a timely manner to meet maturing obligations - **Insurance Risk**: Risk of loss due to deviations between actuarial assumptions and actual experience - **Compliance Risk**: Challenges in complying with laws and regulatory rules across different jurisdictions[232](index=232&type=chunk)[233](index=233&type=chunk)[234](index=234&type=chunk) [Independent Auditor's Report](index=90&type=section&id=%E7%8D%A8%E7%AB%8B%E6%A0%B8%E6%95%B8%E5%B8%AB%E5%A0%B1%E5%91%8A) Ernst & Young, the auditor, confirms that the consolidated financial statements fairly present the group's financial position as of December 31, 2019, and its performance and cash flows for the year, in compliance with the Hong Kong Companies Ordinance - Auditor Ernst & Young believes that the consolidated financial statements truly and fairly reflect the group's consolidated financial position as of December 31, 2019, and its financial performance and cash flows for the year then ended, and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance[250](index=250&type=chunk) - Key audit matters include: 1. **Fair Value Measurement of Investment Properties**: Involves significant management estimates and assumptions regarding rents, capitalization rates, etc 2. **Classification and Measurement of Financial Assets**: Requires significant management judgment in SPPI testing and determining business models 3. **Assessment of Insurance Contract Liabilities**: Involves significant judgment on future uncertain outcomes, such as investment returns, mortality rates, and other actuarial assumptions 4. **Impact of Initial Adoption of HKFRS 16 Leases**: Has a significant impact on the consolidated financial statements and involves significant judgments and estimates[252](index=252&type=chunk)[254](index=254&type=chunk)[256](index=256&type=chunk) [Consolidated Financial Statements](index=97&type=section&id=%E7%B6%9C%E5%90%88%E8%B2%A1%E5%8B%99%E5%A0%B1%E8%A1%A8) This chapter presents the group's audited consolidated financial statements for the year ended December 31, 2019, including the consolidated income statement, statement of comprehensive income, statement of financial position, statement of changes in equity, and statement of cash flows, providing a comprehensive view of the company's financial performance, position, and cash flows [Consolidated Income Statement](index=97&type=section&id=%E7%B6%9C%E5%90%88%E6%90%8D%E7%9B%8A%E8%A1%A8) For 2019, the group achieved total revenue of RMB 142.98 billion, a 30.7% year-on-year increase, with gross profit at RMB 53.96 billion and profit for the year at RMB 20.17 billion, leading to RMB 14.80 billion in profit attributable to parent company shareholders Consolidated Income Statement Summary (RMB Thousand) | Indicator | 2019 | 2018 | | :--- | :--- | :--- | | Revenue | 142,982,128 | 109,351,641 | | Gross Profit | 53,955,433 | 41,623,039 | | Profit Before Tax | 27,517,328 | 21,994,570 | | Profit for the Year | 20,169,377 | 17,009,516 | | Attributable to Parent Company Shareholders | 14,800,912 | 13,406,403 | [Consolidated Statement of Financial Position](index=100&type=section&id=%E7%B6%9C%E5%90%88%E8%B2%A1%E5%8B%99%E7%8B%80%E6%B3%81%E8%A1%A8) As of December 31, 2019, the group's total assets reached RMB 715.68 billion, an increase of 12.0% from the previous year-end, with total liabilities at RMB 534.76 billion and net assets at RMB 180.92 billion, and equity attributable to parent company shareholders growing 13.0% to RMB 122.55 billion Consolidated Statement of Financial Position Summary (RMB Thousand) | Indicator | December 31, 2019 | December 31, 2018 | | :--- | :--- | :--- | | Total Non-Current Assets | 435,948,983 | 362,038,068 | | Total Current Assets | 279,732,213 | 276,845,770 | | **Total Assets** | **715,681,196** | **638,883,838** | | Total Current Liabilities | 268,399,144 | 233,560,489 | | Total Non-Current Liabilities | 266,357,836 | 244,882,326 | | **Total Liabilities** | **534,756,980** | **478,442,815** | | **Total Equity** | **180,924,216** | **160,441,023** | | Equity Attributable to Parent Company Shareholders | 122,552,342 | 108,528,838 | [Consolidated Statement of Cash Flows](index=108&type=section&id=%E7%B6%9C%E5%90%88%E7%8F%BE%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) In 2019, the group reported net cash inflow from operating activities of RMB 7.83 billion, net cash outflow from investing activities of RMB 12.44 billion, and net cash outflow from financing activities of RMB 4.75 billion, with cash and cash equivalents at year-end totaling RMB 81.98 billion Consolidated Statement of Cash Flows Summary (RMB Thousand) | Indicator | 2019 | 2018 | | :--- | :--- | :--- | | Net Cash Inflow from Operating Activities | 7,833,610 | 13,302,392 | | Net Cash Outflow from Investing Activities | (12,436,400) | (11,861,969) | | Net Cash (Outflow) / Inflow from Financing Activities | (4,754,035) | 21,325,302 | | Net (Decrease) / Increase in Cash and Cash Equivalents | (9,356,825) | 22,765,725 | | Cash and Cash Equivalents at Year-End | 81,976,345 | 91,333,170 | [Notes to the Financial Statements](index=113&type=section&id=%E8%B2%A1%E5%8B%99%E5%A0%B1%E8%A1%A8%E9%99%84%E8%A8%BB) This chapter provides detailed notes to the consolidated financial statements, covering the company's basic information, basis of preparation, significant accounting policies, critical accounting judgments and estimates, and detailed breakdowns of various financial statement items, crucial for understanding the company's financial position and operating results [Summary of Significant Accounting Policies](index=118&type=section&id=%E4%B8%BB%E8%A6%81%E6%9C%83%E8%A8%88%E6%94%BF%E7%AD%96%E6%A6%82%E8%A6%81) This section details the group's significant accounting policies, including consolidation, fair value measurement, impairment, revenue recognition, financial instruments, insurance contracts, and leases, noting the adoption of HKFRS 16 Leases from January 1, 2019 - The group adopted HKFRS 16 Leases from January 1, 2019, using the modified retrospective approach, with retrospective adjustments to opening retained earnings but no restatement of comparative information for 2018[294](index=294&type=chunk)[295](index=295&type=chunk) - The group's classification of financial assets depends on contractual cash flow characteristics and business model, categorized as measured at amortized cost, fair value through other comprehensive income (FVOCI), or fair value through profit or loss (FVTPL)[336](index=336&type=chunk) [Operating Segment Information](index=159&type=section&id=%E7%87%9F%E9%81%8B%E6%9D%BF%E5%A1%8A%E8%B3%87%E6%96%99) The group's operations are segmented into Health, Happiness, Insurance, Finance, and Investment, with Insurance, Finance, and Investment forming the Wealth segment; Happiness contributed the most revenue, while Wealth (especially Investment) contributed the most profit in 2019, with Mainland China being the primary source of revenue and non-current assets 2019 Revenue and Segment Performance (RMB Thousand) | Segment | Total Revenue | Segment Performance (Pre-tax) | | :--- | :--- | :--- | | Health | 33,133,048 | 5,092,297 | | Happiness | 67,557,490 | 7,789,179 | | Insurance | 31,261,928 | 3,971,506 | | Finance | 2,492,602 | 1,837,232 | | Investment | 9,615,533 | 10,872,118 | 2019 Revenue Geographical Distribution (RMB Thousand) | Region | Revenue | Proportion | | :--- | :--- | :--- | | Mainland China | 78,837,056 | 55.1% | | Portugal | 18,806,130 | 13.2% | | Other Overseas Countries and Regions | 45,338,942 | 31.7% | | **Total** | **142,982,128** | **100.0%** | [Interest-bearing Bank and Other Borrowings](index=217&type=section&id=%E8%A8%88%E6%81%AF%E9%8A%80%E8%A1%8C%E5%80%9F%E6%AC%BE%E5%8F%8A%E5%85%B6%E4%BB%96%E5%80%9F%E6%AC%BE) As of year-end 2019, the group's total interest-bearing bank and other borrowings increased to RMB 208.29 billion, with approximately 39.7% due within one year, comprising a diversified structure of bank loans, corporate bonds, preference notes, and medium-term notes Borrowing Maturity Structure (RMB Thousand) | Repayment Period | Amount | | :--- | :--- | | Within One Year | 82,738,138 | | In the Second Year | 43,439,152 | | In the Third to Fifth Year | 74,112,282 | | After Five Years | 7,997,485 | | **Total** | **208,287,057** | [Financial Risk Management Objectives and Policies](index=276&type=section&id=%E8%B2%A1%E5%8B%99%E9%A2%A8%E9%9A%AA%E7%AE%A1%E7%90%86%E7%9B%AE%E6%A8%99%E5%8F%8A%E6%94%BF%E7%AD%96) The group manages key financial risks, including interest rate, foreign currency, credit, liquidity, and price risks, through strategies such as balancing fixed and floating rate debt, using derivatives for currency hedging, conducting credit checks, and maintaining financing flexibility - Interest Rate Risk: Approximately **59%** of the group's interest-bearing borrowings are at fixed rates; if interest rates were to increase by **75 basis points**, profit before tax would decrease by approximately **RMB 603 million**[741](index=741&type=chunk)[742](index=742&type=chunk) - Foreign Currency Risk: The group has exchange rate exposure to USD, HKD, and Euro; if the RMB depreciates by **5%** against the USD, profit before tax would increase by approximately **RMB 153 million**; if it depreciates by **5%** against the Euro, profit before tax would decrease by approximately **RMB 433 million**[743](index=743&type=chunk)[744](index=744&type=chunk) - Capital Management: The group manages its capital structure through the total debt to total capital ratio, which was **54%** at the end of 2019, consistent with 2018[764](index=764&type=chunk)[765](index=765&type=chunk)

FOSUN 复星 2019中期報告 復 星 國 際 有 限 公 司 FOSUN INTERNATIONAL LIMITED ( 在香港註冊成立之有限公司 ) (股份代號：00656) 2019 中期報告 復星國際 一家科創驅動的家庭消費產業集團 復星國際在2019年上半年取得歷史最優業績，歸屬於母公司股東之利潤再創歷史新高。更 重要的是，產業運營利潤達人民幣61.2億元，同比增長52%，標誌著我們聚焦全球化產業運 營、打造1+N條產品線的戰略，得到了集團上下良好的貫徹執行並已取得可喜的階段性成果。 在過去幾年，復星致力於提升全球核心業務的運營能力，改善運營效率，打造世界級產品， 增進與客戶的連接，加強全球化品牌營銷能力。我們深信，只有打造極致的產品力，才能形 成強大的品牌；有了強大的品牌，才能智造優質的產業集團和全球生態系統。 報告期內，我們持續推進1+N條產品線戰略，形成了眾多龍頭產品和品牌，比如中國第一個 自主研發的生物類似藥漢利康®、復星聯合健康保險、中國領先的養老服務星堡老年服務、全 球最大的度假村經營者Club Med、三亞旅遊標杆項目三亞亞特蘭蒂斯等。此外，我們將繼續 打造母嬰、體育和寵物產品線， ...

年報 2018 FOSUN 复星 復星國際有限公司 FOSUNITERNATIONAL LIMTED (在香港註冊成立之有限公司) (股份代號 : 00656) 极 智 innovation for excellence | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------|----------------------------------------|--------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | 歸屬於母公司股東之利潤為 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 人 ...